哈尔滨医药2024,Vol.44Issue(1) :11-14.DOI:10.3969/j.issn.1001-8131.2024.01.003

阿托伐他汀钙结合非诺贝特药物治疗冠心病的临床价值

Clinical Value of Atorvastatin Calcium Combined with Fenofibrate in the Treatment of Coronary Atherosclerotic Heart Disease

侯宾 郑方方
哈尔滨医药2024,Vol.44Issue(1) :11-14.DOI:10.3969/j.issn.1001-8131.2024.01.003

阿托伐他汀钙结合非诺贝特药物治疗冠心病的临床价值

Clinical Value of Atorvastatin Calcium Combined with Fenofibrate in the Treatment of Coronary Atherosclerotic Heart Disease

侯宾 1郑方方1
扫码查看

作者信息

  • 1. 平顶山市第二人民医院心血管内二科,河南 平顶山 467000
  • 折叠

摘要

目的 分析阿托伐他汀钙结合非诺贝特药物治疗冠心病(CHD)的临床价值.方法 选取CHD患者 82 例,按随机数字表法分为联合组(n=41)和单一组(n=41),单一组予以阿托伐他汀钙治疗,联合组在单一组基础上结合非诺贝特治疗.对比两组疗效、血脂水平[总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、甘油三酯(TG)]、颈动脉内膜中层厚度(IMT)、血管内皮功能[一氧化氮(NO)、血管内皮素-1(ET-1)]、心功能[左心室收缩末期内径(LVESD)、左室射血分数(LVEF)]水平及不良反应发生率.结果 联合组总有效率 95.12%(39/41)较单一组 80.49%(33/41)高(P<0.05);治疗后,联合组TC、TG水平较单一组低,HDL-C水平较单一组高(P<0.05);治疗后,联合组颈动脉IMT水平较单一组低(P<0.05);治疗后,联合组ET-1 水平较单一组低,NO水平较单一组高(P<0.05);治疗后,联合组LVEF水平较单一组高,LVESD水平较单一组低(P<0.05);两组不良反应对比差异无统计学意义(P>0.05).结论 对CHD患者采用非诺贝特联合阿托伐他汀钙治疗,可提高疗效,能降低血脂水平和颈动脉IMT厚度,并可改善血管内皮功能和心功能,安全性可靠.

Abstract

Objective To analyze the clinical value of atorvastatin calcium combined with fenofibrate in the treatment of coronary atherosclerotic heart disease(CHD).Methods A total of 82 cases of CHD patient were selected and divided into a combination group(n=41)and a single group(n=41)by random number table method.The single group was treated with ator-vastatin calcium,and the combined group was treated with fenofibrate on the basis of a single group.The therapeutic effect,blood lipid levels[total cholesterol(TC),high-density lipoprotein cholesterol(HDL-C),triglyceride(TG)],carotid intimax-media thickness(IMT),vascular endothelial function[nitric oxide(NO),endothelin-1(ET-1)],cardiac function[left ventricular end-systolic diameter(LVESD),and left ventricular ejection fraction(LVEF)]were compared between the two groups Number and the incidence of adverse reactions.Results The total effective rate of the combination group95.12%(39/41)was higher than that of the single group 80.49%(33/41)(P<0.05).After treatment,the TC and TG levels in the combination group were lower than those in the single group,and the HDL-C level was higher than those in the single group(P<0.05).After treatment,the level of carotid IMT in the combination group was lower than that in the single group(P<0.05).After treatment,the ET-1 lev-el in the combination group was lower than that in the single group,and the NO level was higher than that in the single group(P<0.05).After treatment,the LVEF level in the combination group was higher than that in the single group,and the LVESD level was lower than that in the single group(P<0.05).There was no significant difference in adverse reactions be-tween the two groups(P>0.05).Conclusion Fenofibrate combined with atorvastatin calcium in the treatment of CHD patients can improve the efficacy,reduce the blood lipid levels and carotid IMT thickness,and improve the vascular endothelial func-tion and cardiac function,which is safe and reliable.

关键词

阿托伐他汀钙/非诺贝特/冠心病/心功能

Key words

Atorvastatin calcium/Fenofibrate/Coronary atherosclerotic heart disease/Cardiac function

引用本文复制引用

出版年

2024
哈尔滨医药
哈尔滨市医学会

哈尔滨医药

影响因子:0.697
ISSN:1001-8131
参考文献量12
段落导航相关论文